---
title: relapse refractory of treatment of acute lymphoblastic leukemia (ALL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> 🌱 來自: [[treatment of acute lymphoblastic leukemia (ALL)]]

# relapse refractory of treatment of acute lymphoblastic leukemia (ALL)

*   salvage therapy
	* FLAG （fludarabine + cytarabine + G-CSF)
	* mitoxantrone 合併cytarabine、
	* 高劑量 cytarabine（3 g/m2 Q12H）

> 多數病人對第二線化療的反應不佳。

*   then 👉 allogeneic HSCT

### B cell: 

*   [[blinatumomab]] 🦷bli-na-**TU**-mo-mab
    *   (CD19 BiTE-bispecific T-cell engager; NEJM2017;376:836)
*   [[inotuzumab]] 🐷ino-**TU**-zu-mab
    *   (CD22 Ab drug conjugate; NEJM2016;375:740)
*   tisagenlecleucel and brexucabtagene autoleucel
    *   (CD19 CAR-T, NEJM 2018;378:449; Lancet 2021;398:491)
*   TKI+chemo/steroids (Ph ⊕t(9;22) only)

### T cell

*   nelarabine
*   ± cyclophosphamide
*   etoposide

### Both B & T cell: 

*   chemo including
*   : high dose cytarabine regimens;
*   : clofarabine
